Member Info for Intrigue

OK - so I've now got my PBX shares on II - can sell at 12p.

Nor me - I keep checking. Must be soon surely.

Thank you. Yes, I saw conflicting info on different sites, think the other figure I saw must have been quoted in Euros as it's on a European stock exchange. Cheers.

Can someone confirm what the current share price is here? Plus, is it listed in £ or Euros?

I believe most PIs will hold less than 100,000 shares here. I'm about that amount, but built up over several years. To buy that amount in one lump (£61K) is, I'd say, a considerable buy for most - a decent top up for a director however.

Someone just bought. 100,000 shares at 61p (£61K)

...that trades are going 'Negotiated Deal' today. Can anyone buying recently confirm?

Thanks - holdings announcement didn't specify their previous holding so though they must be new - grateful for the clarification.

Yorkshire Seedcorn just bought nearly 10% of the company?

This one for Greece, Cyprus and, potentially, the Gulf States.

No missed that one - thanks

Buy of 95,000 shares at 97.5p just gone through - wish I had that sort of cash free.

Interesting interview. plus "Hopefully a few Christmas surprises for people" says O'Hara. What a tease!

$1 million of next 6-12 months is great news - swift step up in income for NIPT

Buying at 103p now - moving up swiftly today. Low volumes, but background buyer perhaps, that or lack of stock.

May have been intra-day but closing price was 97p according to my records. But as you say, water under the bridge - let' get there again and beyond.

Buying pressure building nicely - once past 85p the next resistance level is at the all-time high of 97p.

C'mon OPTI

and they look good! A fecking profit - quite a turnaround.

64/65p now

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in our products and the opportunity to meet with senior US and Asian decision makers at Supply Side West. We are particularly pleased by the commitment shown by our partners who have invested significant financial resources in providing exhibition space, appointed and trained new personnel, and developed new products at their own cost, to support the commercialisation of our products. We believe this reflects the high level of confidence in the commercial potential of our products. As we build the range of applications and geographic scope of LPLDL® and SlimBiome® with new manufacturing and distribution partners; the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms."